Trial Profile
An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tabelecleucel (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Atara Biotherapeutics
- 26 Sep 2022 Status changed from completed to discontinued.
- 21 Sep 2021 Status changed from active, no longer recruiting to completed.
- 01 Feb 2021 Status changed from recruiting to active, no longer recruiting.